DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

Information source: Shinshu University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis

Intervention: Denosumab treatment in osteoporotic patients (Drug); Teriparatide treatment in osteoporotic patients (Drug); Denosumab and teriparatide treatment in osteoporotic patients (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Shinshu University

Overall contact:
Yukio Nakamura, MD, PhD, Phone: +81-263-37-2659, Email: yxn14@aol.jp

Summary

It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.

Clinical Details

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Changes of bone mineral density

Secondary outcome: Changes of bone turnover markers

Eligibility

Minimum age: 1 Year. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Osteoporotic patients

Exclusion Criteria:

- none

Locations and Contacts

Yukio Nakamura, MD, PhD, Phone: +81-263-37-2659, Email: yxn14@aol.jp

Yukio Nakamura, Matsumoto, Nagano 3908621, Japan; Recruiting
Yukio Nakamura, MD, PhD, Phone: +81-263-37-2659, Email: yxn14@aol.jp
Yukio Nakamura, MD, PhD, Principal Investigator
Additional Information

Starting date: May 2014
Last updated: May 19, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017